Study guide
14.1 Alcohol-Associated Liver Disease: Staging, Scoring & Management
Certified Addictions Registered Nurse - Advanced Practice CARN-AP
Track your progress as you read
Finished sections get a check mark.
1 Introduction: The CARN-AP Examination & Foundations of Advanced Addictions Practice
About the CARN-AP Examination: Blueprint, Scoring & Eligibility The Neurobiology of Addiction: Binge, Withdrawal & Preoccupation Screening, SBIRT & the ASAM Criteria Levels of Care
2 Chapter 1: Opioid Use Disorder: Assessment, Overdose Response & Methadone Maintenance
1.1 OUD Assessment, DSM-5-TR Diagnostic Criteria, and Clinical Opiate Withdrawal Scale (COWS) 1.2 Methadone Pharmacology, OTP Federal Regulations, QTc Prolongation & CYP450 Interactions 1.3 Opioid Overdose Assessment, Harm Reduction, Naloxone Formulations & Nalmefene
3 Chapter 2: Buprenorphine Protocols, Long-Acting Injectables & Naltrexone
2.1 Buprenorphine Pharmacology, Standard Office/Home Induction & Precipitated Withdrawal Management 2.2 Low-Dose Micro-Induction (Bernese Method) & Fentanyl Transition Strategies 2.3 Long-Acting Injectable Buprenorphine (Sublocade, Brixadi) & Extended-Release Naltrexone (Vivitrol)
4 Chapter 3: Alcohol Use Disorder: Neurobiology, Assessment & Acute Withdrawal
3.1 AUD Neurobiology, Epidemiology, Screening Instruments (AUDIT, AUDIT-C, CAGE) & Laboratory Biomarkers 3.2 Alcohol Withdrawal Syndrome, CIWA-Ar Protocol, Symptom-Triggered Benzodiazepine Regimens & Delirium Tremens 3.3 Wernicke-Korsakoff Syndrome, High-Dose Parenteral Thiamine Protocols & Acute Medical Complications
5 Chapter 4: Medications for Alcohol Use Disorder (MAUD)
4.1 Oral and Injectable Naltrexone for AUD: Mechanism, Prescribing Protocols & Clinical Efficacy 4.2 Acamprosate Calcium: NMDA Modulation, Renal Dosing Parameters & Abstinence Maintenance 4.3 Disulfiram and Second-Line / Off-Label MAUDs: Topiramate, Gabapentin & Baclofen
6 Chapter 5: Stimulant, Sedative-Hypnotic & Synthetic Substance Use Disorders
5.1 Stimulant Use Disorder (Cocaine & Methamphetamine): Neurotoxicity, Medical Emergencies & Evidence-Based Interventions 5.2 Sedative, Hypnotic, and Anxiolytic Disorders: Dependence Physiology, Risks & Outpatient Tapering Protocols 5.3 Emerging Synthetic Drugs: Fentanyl Analogues, Synthetic Cathinones, Cannabinoids & Xylazine-Associated Necrotic Wounds
7 Chapter 6: Tobacco and Cannabis Use Disorders: Evidence-Based Pharmacotherapy & Interventions
6.1 Tobacco Use Disorder & Nicotine Dependence: Dual NRT, Varenicline & Bupropion Prescribing Protocols 6.2 Cannabis Use Disorder, Synthetic Cannabinoids & Cannabinoid Hyperemesis Syndrome 6.3 Behavioral Therapies in Substance Use: Motivational Interviewing, CBT & Contingency Management
8 Chapter 7: Psychiatric Differential Diagnosis & Medical Mimics in Addictions
7.1 Diagnostic Formulation: Primary vs. Substance-Induced Psychiatric Disorders & The 30-Day Rule 7.2 Endocrine, Neurological, and Metabolic Mimics of Substance Intoxication and Withdrawal 7.3 Decisional Capacity, Competency, and Involuntary Commitment in Acute Addiction Practice
9 Chapter 8: Co-Occurring Psychiatric Disorders: Integrated Treatment Planning
8.1 Integrated Dual Diagnosis Treatment (IDDT) Framework & High-Prevalence Mood / Anxiety Co-Occurring Disorders 8.2 Complex Severe Mental Illness: Psychotic Disorders, Bipolar Disorder & Borderline Personality in Addictions 8.3 Trauma-Informed Care, PTSD, and Addictions: Evidence-Based Integrated Psychotherapy
10 Chapter 9: Pain Management in Substance Use Disorders & CDC 2022 Guidelines
9.1 CDC 2022 Clinical Practice Guideline for Prescribing Opioids for Chronic Pain: Individualized Assessment vs. Hard Caps 9.2 Multimodal Non-Opioid Pharmacotherapy, Interventional Modalities & Non-Pharmacological Strategies 9.3 Acute Pain Management in Patients on Maintenance MOUD (Methadone, Buprenorphine, Naltrexone)
11 Chapter 10: Perinatal Substance Use, Neonatal Abstinence & Infectious Complications
10.1 Perinatal Substance Use Disorder: ACOG/ASAM Guidelines, MOTHER Trial & Maintenance MOUD 10.2 Neonatal Abstinence Syndrome (NAS/NOWS): Finnegan Scoring vs. Eat, Sleep, Console (ESC) & Breastfeeding 10.3 Infectious Complications in People Who Inject Drugs: Viral Hepatitis, HIV, Endocarditis & PrEP/PEP
12 Chapter 11: Federal Regulations, Confidentiality & Controlled Substance Prescribing
11.1 Controlled Substances Act, DEA Registration, Schedule Classifications & MAT Act of 2023 11.2 Confidentiality of Substance Use Disorder Patient Records: 42 CFR Part 2 (2024 Final Rule) & HIPAA Harmonization 11.3 Prescription Drug Monitoring Programs (PDMP) & Urine Drug Testing (UDT) Interpretation
13 Chapter 12: APRN Scope of Practice, Ethical Foundations, Harm Reduction & Research Literacy
12.1 APRN Scope of Practice, Prescriptive Authority & Collaborative Practice Regulations 12.2 Ethical Dilemmas in Addictions Nursing: Stigma, Autonomy, Justice, and Maternal/Fetal Rights 12.3 Harm Reduction Philosophy, Syringe Service Programs, Drug Checking & Overdose Prevention 12.4 Landmark Clinical Trials & Research Literacy in Addictions Medicine
14 Chapter 13: Stimulant Use Disorder in Depth — Methamphetamine, Withdrawal, Treatment & Harm Reduction
13.1 Methamphetamine Use Disorder: Pharmacology, Medical & Psychiatric Sequelae 13.2 Stimulant Withdrawal, Craving & Contingency Management 13.3 Pharmacotherapy Research for Stimulant Use Disorder 13.4 Stimulant Harm Reduction, Overamping & Patient Education
15 Chapter 14: Medical Consequences of Alcohol Use — Liver, Heart, Cancer & Nutrition
14.1 Alcohol-Associated Liver Disease: Staging, Scoring & Management 14.2 Cardiovascular, Oncologic & Nutritional Consequences of Alcohol
16 Chapter 15: Brief Intervention, Drinking Goals & Recovery Support in Alcohol Use Disorder
15.1 Brief Intervention, Drinking Goals & Shared Decision Making in AUD 15.2 Relapse Prevention, Mutual-Help Programs & Recovery Support
17 Chapter 16: Tobacco Use Disorder in Depth — Neurobiology, Assessment & Special Populations
16.1 Nicotine Neurobiology, Epidemiology & the Tobacco Product Landscape 16.2 Tobacco Assessment & Behavioral Treatment: 5 A's, Quitlines & Incentives 16.3 Tobacco Treatment in Special Populations & Co-Occurring Disorders
18 Chapter 17: Cannabis Use Disorder in Depth — Products, Treatment & Policy
17.1 Cannabinoid Pharmacology, Potency & the Modern Product Landscape 17.2 Cannabis Use Disorder: Epidemiology, Assessment & Treatment Evidence 17.3 Medical Cannabis, Legalization Policy, Adolescent Risk & Patient Education
19 Chapter 18: Other Use Disorders — Inhalants, Hallucinogens, Process Addictions & Prescription/OTC Misuse
18.1 Inhalant Use Disorder: Volatile Solvents, Nitrous Oxide & Alkyl Nitrites 18.2 Hallucinogens & Dissociatives: Classic Psychedelics, PCP, Ketamine & HPPD 18.3 Process (Behavioral) Addictions: Gambling Disorder, Gaming & Compulsive Behaviors 18.4 Prescription & Over-the-Counter Substance Misuse: Opioids, Stimulants, Kratom & DXM
20 Chapter 19: Educating Patients, Families & the Public (CARN-AP Activity Area III)
19.1 Designing Health Teaching: Literacy, Readiness, Culture & Teach-Back 19.2 Medication Education, Informed Consent & Informed Refusal 19.3 Family & Support-System Education: CRAFT, Al-Anon & Overdose Prevention Teaching 19.4 Public, Professional & Anticipatory Guidance: Prevention and Advocacy Teaching
21 Chapter 20: Consultation, Collaboration & Care Coordination (CARN-AP Activity Area IV)
20.1 The APRN Consultation Process & Communicating Recommendations 20.2 Interprofessional Collaboration, Care Coordination & Transitions of Care 20.3 Community Resources, Systems Navigation & Collaborative Documentation
22 Chapter 21: Quality Improvement, Evidence & Leadership in Addictions Nursing (CARN-AP Activity Area V)
21.1 Outcome Measurement & Continuous Quality Improvement in Addictions Care 21.2 Policy Advocacy, Leadership & the Determinants of Addiction
14.1 Alcohol-Associated Liver Disease: Staging, Scoring & Management
Key Takeaways Explain This Topic AI
Alcohol-associated liver disease progresses through steatosis, which is reversible within weeks of abstinence, to steatohepatitis, fibrosis and cirrhosis.
An AST to ALT ratio greater than 2 with both values usually below 300 to 400 IU/L is the classic biochemical signature of alcohol-associated hepatitis.
A Maddrey discriminant function of 32 or higher identifies severe alcohol-associated hepatitis with high short-term mortality and is the historical threshold for considering corticosteroids.
The Lille score at day 7 determines whether corticosteroids are working; a score of 0.45 or higher indicates non-response and supports stopping steroids.
Naltrexone and acamprosate can both be used in compensated liver disease, but acamprosate is preferred when hepatic function is significantly impaired because it is cleared entirely by the kidneys.
Last updated: September 2026
14.1 Alcohol-Associated Liver Disease: Staging, Scoring & Management
Quick Answer: Alcohol-associated liver disease (ALD) runs steatosis → steatohepatitis → fibrosis → cirrhosis . Steatosis reverses within 4 to 6 weeks of abstinence . Alcohol-associated hepatitis shows AST:ALT greater than 2 with values usually below 300 to 400 IU/L , plus bilirubin elevation and neutrophilia. Severity is graded with the Maddrey discriminant function (32 or higher = severe) and MELD ; the Lille score at day 7 (0.45 or higher = non-response) decides whether to continue corticosteroids. Abstinence is the only therapy that changes long-term survival , which makes alcohol use disorder treatment a hepatology intervention.
1. The Spectrum
Stage Pathology Reversibility Typical findings
Steatosis Macrovesicular fat accumulation Fully reversible in 4 to 6 weeks of abstinence Often asymptomatic; mild transaminase elevation; hepatomegaly
Alcohol-associated steatohepatitis Ballooning degeneration, Mallory-Denk bodies, neutrophilic infiltrate Partially reversible Jaundice, tender hepatomegaly, fever, leukocytosis
Fibrosis Pericellular and perivenular collagen deposition Partially reversible early Elevated FIB-4; increased liver stiffness on elastography
Cirrhosis Regenerative nodules, architectural distortion Not reversible, but decompensation can regress with abstinence Ascites, varices, encephalopathy, coagulopathy, thrombocytopenia
Only a minority of people with heavy alcohol use develop cirrhosis. Risk multipliers the APRN should assess and teach: female sex (greater injury per gram of alcohol), obesity and metabolic dysfunction , hepatitis C or B coinfection , daily rather than episodic drinking , drinking outside meals , and genetic variants such as PNPLA3.
2. Interpreting the Laboratory Pattern
AST:ALT greater than 2 is the signature. It arises because alcohol depletes pyridoxal 5'-phosphate, which ALT synthesis requires more than AST, and because alcohol injures mitochondria, releasing mitochondrial AST.
Magnitude matters. In alcohol-associated hepatitis, AST rarely exceeds 300 to 400 IU/L . Transaminases above 1,000 IU/L point to acetaminophen toxicity, ischemic hepatitis or acute viral hepatitis — an important distinction because a patient who drinks heavily may have all three risks at once.
GGT is sensitive for heavy drinking but has poor specificity; it rises with metabolic liver disease, enzyme-inducing drugs and biliary disease.
Phosphatidylethanol (PEth) is a direct alcohol biomarker with a detection window of roughly 2 to 4 weeks , substantially more specific than GGT or carbohydrate-deficient transferrin, and increasingly used in transplant evaluation.
Platelet count falling below 150,000 in a heavy drinker is an early clue to portal hypertension.
3. Severity Scoring
Score Inputs Threshold Use
Maddrey discriminant function Prothrombin time and total bilirubin 32 or higher = severe Historical trigger for considering corticosteroids
MELD / MELD 3.0 Bilirubin, INR, creatinine, sodium (plus albumin and sex in MELD 3.0) Higher scores predict short-term mortality; used for transplant allocation Prognosis and listing
Lille score Age, albumin, bilirubin at day 0 and day 7, creatinine, prothrombin time 0.45 or higher = non-response Decide whether to stop corticosteroids at day 7
Glasgow alcoholic hepatitis score Age, white cell count, urea, INR, bilirubin 9 or higher identifies severe disease Alternative severity index
Corticosteroids (prednisolone 40 mg daily for 28 days) may be considered in severe alcohol-associated hepatitis without contraindication. They improve short-term but not long-term survival, and are withheld in active infection, gastrointestinal bleeding, and untreated hepatorenal syndrome. Pentoxifylline is no longer recommended. N-acetylcysteine has been studied as an adjunct.
4. Alcohol Use Disorder Pharmacotherapy in Liver Disease
This is the APRN's decision and a recurring exam scenario.
Medication Compensated liver disease Significant hepatic impairment / cirrhosis
Naltrexone Reasonable with monitoring; the old blanket contraindication has softened, and hepatotoxicity was seen with doses far above 50 mg Generally avoided in acute hepatitis and decompensated cirrhosis
Acamprosate Effective; no hepatic metabolism Preferred when hepatic clearance is impaired, provided creatinine clearance exceeds 30 mL/min; contraindicated below 30 mL/min
- Disulfiram Avoid Contraindicated — hepatotoxic and dangerous in advanced disease
- Baclofen Off-label option The agent with the most randomized data specifically in cirrhosis; renally cleared
- Topiramate / gabapentin Off-label options Use caution; both can worsen encephalopathy-like cognitive effects
- 5. Transplant and the Abstinence Question
The historical "six-month rule" — six months of documented abstinence before listing — has been substantially revised. Multiple transplant centers now perform early liver transplantation for carefully selected patients with severe alcohol-associated hepatitis who do not respond to medical therapy, using psychosocial assessment rather than a fixed abstinence interval. The APRN's contribution is the psychosocial and addiction assessment: insight, support system, prior treatment response, co-occurring disorders, and a concrete relapse-prevention plan including medication for alcohol use disorder. A blanket statement that a patient "must be sober six months" is outdated and, on the exam, wrong.